Diabetes Metab J.  2012 Dec;36(6):462-463. 10.4093/dmj.2012.36.6.462.

Response: The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone (Diabetes Metab J 2012;36:371-8)

• Song SO
• Kim KJ
• Lee BW

• KMID: 2174373
• DOI: http://doi.org/10.4093/dmj.2012.36.6.462

Abstract

No abstract available.

MeSH Terms

Thiazolidinediones
Urinary Bladder
Urinary Bladder Neoplasms
Thiazolidinediones

Reference

1. World Health Organization. WHO report on the global tobacco epidemic, 2011. cited 2012 Nov 20. Available from: http://www.who.int/tobacco/surveillance/policy/country_profile/kor.pdf.

2. Dowdy D. Tobacco smoking and bladder cancer. JAMA. 2011. 306:2216–2217. author reply 2217.

3. Zhu Z, Shen Z, Lu Y, Zhong S, Xu C. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2012. 98:159–163.

4. Kermode-Scott B. Meta-analysis confirms raised risk of bladder cancer from pioglitazone. BMJ. 2012. 345:e4541.

5. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012. 35:278–280.

6. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012. 55:1953–1962.

7. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011. 34:916–922.

8. Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 2012. 344:e3645.